X-BODY set to introduce Protein Chain Reaction antibody discovery platform

The platform’s Protein Chain Reaction allows for screening against cell surface targets in their native state on live cells or purified target proteins.

X-BODY claims that its platform employs the high throughput SRU BIND protein detection system to screen for high affinity antibodies.

X-BODY, in collaboration with SRU Biosystems, has validated a novel BIND Biosensor design for use with the commercially available SRU BIND Reader that results in a >500-fold increase in sensitivity over SRU’s previous sensor technology.

The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated 384-well or 1536-well microplate format.

X-BODY’s Protein Chain Reaction screening system, with deep sequencing of thousands of hits, allows for the rapid identification of high quality leads.

The company claims that its new its platform has high affinity, high selectivity, species cross-reactivity, broad epitope coverage, low immunogenicity

X-BODY chief business officer Tod Woolf said that they believe their platform provides a path to high quality human antibody therapeutic lead candidates against challenging target proteins.